DarioHealth Corp. (NASDAQ:DRIO) Stock Has Average Target Price of $9.00 According to Analysts

DarioHealth Corp. (NASDAQ:DRIO) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $9.00.

DRIO has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (e+)” rating on shares of DarioHealth in a research report on Tuesday, October 6th. Alliance Global Partners began coverage on DarioHealth in a report on Wednesday, August 19th. They issued a “buy” rating and a $12.00 target price for the company. TD Cowen decreased their price target on DarioHealth from $11.00 to $8.00 and set a “hold” rating for the company in a research report on Wednesday, August 12th. Finally, BTIG Research assumed coverage on DarioHealth in a report on Tuesday. They set a “buy” rating and a $6.00 price target on the stock.

DarioHealth Stock Down 9.8%

DarioHealth stock opened at $3.40 on Tuesday. DarioHealth has a fifty-two week low of $3.01 and a fifty-two week high of $16.44. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.92 and a current ratio of 2.31. The firm’s 50-day simple moving average is $6.30 and its 200 day simple moving average is $7.97. The stock has a market cap of $33.32 million, a PE ratio of -0.55 and a beta of 1.18.

DarioHealth (NASDAQ:DRIO) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($1.22) by $0.37. The firm had revenue of $5.18 million during the quarter, compared to analyst estimates of $5.92 million. DarioHealth had a negative net margin of 169.87% and a negative return on equity of 54.81%. Research analysts predict that DarioHealth will post -2.94 EPS for the current fiscal year.

Institutional Investors Weigh In On DarioHealth

An institutional investor recently bought a new position in DarioHealth stock. BlackRock Inc. bought a new stake in shares of DarioHealth Corp. (NASDAQ:DRIO) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 37,796 shares of the company’s stock, valued at approximately $249,000. BlackRock Inc. owned about 0.51% of DarioHealth at the end of the most recent reporting period. Hedge funds and other institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth Corp. is a digital health company that develops technology-enabled solutions for managing chronic conditions. Its platform combines connected medical devices, mobile applications, data analytics and personalized coaching to help individuals monitor and improve their health.

The company’s offerings have focused on conditions including diabetes, hypertension, musculoskeletal disorders and behavioral health. Products and services may include connected blood glucose and blood pressure monitoring, digital programs for pain and mobility management, health coaching, educational content and tools that support healthier daily habits.